论文部分内容阅读
目的:探讨并分析重症肌无力(MG)患者的免疫指标和临床治疗效果。方法:选取我院2010年6月~2014年6月接收的200例重症肌无力患者,在治疗前和治疗后采用细胞仪检测外周血CD3、CD4和CD8及采用比浊法检测IgG、IgA和IgM,进行分类比较其变化。结果:全身型重症肌无力患者的IgG、IgA较眼肌型高(P<0.05),差异具有统计学意义。在治疗前后的免疫指标(CD3、CD4、CD8、IgG、IgA及IgM)和临床资料(男/女、眼肌型/全身型、检测时病程、检测时年龄)的对比中,差异无统计学意义(P>0.05)。在体液免疫低下组中,用丙种球蛋白治疗的缓解率比未用丙种球蛋白组的缓解率高(P<0.01),差异具有统计学意义。结论:重症肌无力患者免疫指标IgG、IgA、IgM、CD3、CD4、CD8虽然不能作为重症肌无力患者的病情和疗效的唯一评价指标,但对指导治疗具有一定的参考价值,且体液免疫低下者用丙球蛋白的疗效较好。
Objective: To investigate and analyze the immune index and clinical therapeutic effect in patients with myasthenia gravis (MG). Methods: A total of 200 patients with myasthenia gravis received in our hospital from June 2010 to June 2014 were enrolled in this study. Peripheral blood CD3, CD4 and CD8 were detected by cytometry before and after treatment. The levels of IgG, IgA and IgM, classification to compare the changes. Results: IgG and IgA in patients with systemic myasthenia gravis were significantly higher than those in ocular muscles (P <0.05). The difference was statistically significant. There were no significant differences in the immune parameters (CD3, CD4, CD8, IgG, IgA and IgM) before and after treatment and clinical data (male / female, ocular / systemic, duration of test, age at test) Significance (P> 0.05). In the low humoral immune group, the response rate with gamma globulin was higher (P <0.01) than that without gamma globulin (P <0.01). The difference was statistically significant. CONCLUSION: The immune indexes IgG, IgA, IgM, CD3, CD4 and CD8 in patients with myasthenia gravis can not be used as the sole evaluation index of disease and curative effect in patients with myasthenia gravis, but they have certain reference value for guiding therapy, and those with low humoral immunity C globulin with better efficacy.